Researchers are hard at work to find a biomarker for Parkinson's disease (PD), a critical and missing tool in the development of disease-modifying treatments. Reliable and consistent biomarkers for PD would allow scientists to predict, objectively diagnose, and monitor the disease, and to determine which medications work and which don’t. Significant advances in this search have been made over the past year, but there is still much work to be done.
On Thursday, June 27, at 12 p.m. ET, we’ll address the latest developments in the field, highlighting work done in the Parkinson’s Progression Markers Initiative (PPMI), the Foundation’s landmark biomarker study which completed recruitment in April. We’ll also discuss a first-of-its-kind collaboration called BioFIND, a multi-site study exclusively focused on identifying entirely new PD biomarkers, driven by MJFF and the NIH National Institute of Neurological Disorders and Stroke (NINDS).
Foundation Contributing Editor Dave Iverson will moderate a conversation with PPMI Principal Investigator Ken Marek, MD, and MJFF Vice President of Research Programs Mark Frasier, PhD. A Q&A with participants will follow.
We invite you to register to participate!
The Webinar will:
- Explain what a biomarker is, and why finding one would be so critical to developing new treatments.
- Discuss the state of the current pipeline of potential biomarkers.
- Provide an update of PPMI’s progress, which is now expanding on the heels of successful recruitment.
- Explain how you can help with the biomarker search.
You can learn more ahead of the Webinar by checking out MJFF resources online. Read about the new study arm of PPMI on our blog, or check out our latest newsletter’s cover story on PPMI’s progress.